Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GKL-006Allo in Ankylosing Spondylitis
NCT07915544Phase 1Not yet recruiting
- Sponsor
- GenePlus
- Start
- Nov 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GKL-006Allo in ankylosing spondylitis (AS), sponsored by GenePlus. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse Events and Serious Adverse Events at 52 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
GKL-006Allo
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT07915544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915544.